← Leaderboards
Daniel C Medynski
Proteomtech, Inc.
$950,197
Attributed
$950,197
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$950,197 · 3
By mechanism
R44$750,197 · 1
R43$200,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionLaboratory MouseAthymic MouseProtein FoldingAntineoplasticsNeoplasm /Cancer PharmacologyPharmacokineticsDrug Screening /EvaluationInclusion BodyInjection /InfusionProtein IsoformsEscherichia ColiMacular DegenerationMyocardial InfarctionPeptide Chemical SynthesisPharmacologyPlasmidsPolymerase Chain ReactionProtein PurificationProtein SequencePsoriasisRecombinant ProteinsRheumatoid ArthritisSite Directed Mutagenesis
Grant awards (4)
Recombinant h-VEGI as an Anit-Angiogenesis Therapeutic$353,094
R44 · FY2005 · CA
Recombinant h-VEGI as an Anit-Angiogenesis Therapeutic$397,103
R44 · FY2004 · CA
Bioengineering Prourokinase for Improved Fibrinolysis$100,000
R43 · FY2004 · HL
Recombinant h-VEGI as an Anticancer Therapeutic$100,000
R43 · FY2003 · CA